Nepro® LP Vanilla flavor 220mL
NEPRO LP (LOWER PROTEIN)
SCIENTIFICALLY DESIGNED TO MEET THE NUTRIENT NEEDS FOR PEOPLE WITH KIDNEY DISEASE (NONDIALYZED)
- Complete renal nutrition for oral or tube feeding, as supplement or sole source nutrition
- Unique KidneyCare System with heart healthy fat blend, low-GI§ CARBSTEADY® system and modified electrolytes (low phosphorus, potassium, sodium) to improve nutritional status and outcomes of CKD patients
- High in calories (1.82kcal/ml), while provide lower levels of protein§§ (9.94g/220ml)
- Helps slow the progression of chronic kidney disease and maintain nutrition status of non-dialyzed people with reduced kidney functions1
IMPORTED FROM THE NETHERLANDS
Ingredients
Water, maltodextrin, VEGETABLE OIL (high oleic sunflower oil, canola oil), milk protein isolate, isomaltulose, sucrose, glycerine, sodium caseinate, fructo-oligosaccharides, MINERALS (potassium citrate, sodium citrate, magnesium chloride, potassium chloride, magnesium phosphate dibasic, ferrous sulfate, zinc sulfate, cupric sulfate, manganese sulfate, chromium chloride, potassium iodide, sodium molybdate, sodium selenate), emulsifier (soy lecithin), flavoring, choline chloride, VITAMINS (ascorbic acid, niacinamide, calcium pantothenate, pyridoxine hydrochloride, thiamine hydrochloride, riboflavin, Vitamin E, Vitamin A palmitate, folic acid, biotin, phylloquinone, Vitamin D3, cyanocobalamin), L-carnitine, stabilizer (carrageenan) and taurine.
Contains milk and soy ingredients.
Nutrition Information
RELATED PRODUCTS
RELATED CONTENT
Examining guidelines and new evidence in oncology nutrition
Examining guidelines and new evidence in oncology nutrition
- Logo
-
- Main Image
-
- Tagname
- Article
- Logo link
- title
- Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care
- Content Reference
- /content/an/hcpproconnect/hk/en/home/adult/resources/public/Examining-guidelines-and-new-evidence-in-oncology-nutrition-a-position-paper-on-gaps-and-opportunities-in-multimodal-approaches-to-improve-pati
- Abstract
-
Malnutrition, muscle loss, and cachexia are prevalent in cancer and remain key challenges in oncology today. These conditions are frequently underrecognised and undertreated and have devastating consequences for patients. Early nutrition screening/assessment and intervention are associated with improved patient outcomes.
- Publish Date:
- Oct 2021
The Benefits of Beta-Hydroxy-Beta-Methylbutyrate (or HMB)
- Logo
-
- Main Image
-
- Tagname
- ARTICLE
- Logo link
- title
- The Benefits of Beta-Hydroxy-Beta-Methylbutyrate (or HMB)
- Content Reference
- /content/an/hcpproconnect/hk/en/home/adult/resources/public/hmb-article
- Abstract
-
The benefits of oral nutritional supplements containing HMB are supported by evidence from over 18 clinical studies,9-27 read this short article to learn more about the benefits of HMB.
- Publish Date:
The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition
The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition
- Logo
-
- Main Image
-
- Tagname
- Article
- Logo link
- title
- The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition
- Content Reference
- /content/an/hcpproconnect/hk/en/home/adult/resources/public/The-Underappreciated-Role-of-Low-Muscle-Mass-in-the-Management-of-Malnutrition
- Abstract
-
This opinion article, published in Journal of American Medical Directors Association (JAMDA), addresses the role of muscle mass in improving health outcomes in a variety of disease states. It also offers strategies you can use to help patients manage low muscle mass and prevent muscle loss.
- Publish Date:
- Jan 2019
Footnotes:
§ GI: Nepro®LP = 44
§§ Nepro®LP has 44% less protein compared to Nepro®HP (9.94g vs 17.82g per serving)
References:
- Kelly, Owen J et al. Journal of personalized medicine vol. 11,12 1360. 14 Dec. 2021.
HKG.2025.58198.AND.1
Stay Connected